Blocking HDAC11 Slows Muscle Aging and Cuts Mortality in Old Mice

Sarcopenia — the progressive loss of skeletal muscle mass and strength that accompanies aging — affects hundreds of millions of older adults worldwide and currently has no approved pharmacological treatment beyond exercise and nutrition. This study from Spanish researchers published in Geroscience asks whether eliminating a single epigenetic enzyme, histone deacetylase 11 (HDAC11), can meaningfully slow that decline. HDAC11 is the newest and most structurally distinct member of the HDAC family, classified alone in class IV, and is highly expressed in skeletal muscle. Unlike classical HDACs, it functions primarily as a long-chain fatty acid deacylase with potent demyristoylation activity, meaning it removes fatty acid chains from proteins rather than simply stripping acetyl groups from histones.

The study used total Hdac11 knockout (HDAC11−/−) mice aged to 20–22 months, compared against wild-type (WT) controls of the same age, with young WT mice (3–4 months) serving as a baseline reference. Detailed histological, molecular, functional, and lipidomic analyses were performed on soleus (slow-twitch) and tibialis anterior (fast-twitch) muscles. A key early finding was survival: 27% of WT mice died before 22 months from spontaneous tumors or age-associated pathologies requiring euthanasia, while zero HDAC11−/− mice died prematurely. Body weight and gross organ measurements were indistinguishable between genotypes, ruling out developmental or compensatory effects.

At the histological level, whole-muscle cross-sectional area in HDAC11−/− animals remained significantly closer to that of young WT mice in both soleus and tibialis anterior. Fiber-type-specific analysis revealed that type IIa fibers in HDAC11−/− soleus were approximately 20% larger than in old WT mice, and type IIb fibers in tibialis anterior were 26% larger — precisely the fiber subtypes that showed significant age-related atrophy in controls. Protein levels of muscle atrophy markers MuRF1 and cathepsin L (CTSL1) were significantly reduced in HDAC11−/− muscles, indicating suppressed ubiquitin-proteasomal and autophagic-lysosomal degradation pathways. The neuromuscular junction fragmentation that normally increases with age was significantly attenuated in knockout animals, though the number and diameter of myelinated axons in peripheral nerves were unaffected, pointing to a primarily postsynaptic protective mechanism.

The muscle stem cell (satellite cell) pool, which typically contracts with age and limits regenerative capacity, was better preserved in HDAC11−/− mice. After experimental injury (cardiotoxin injection), old knockout mice showed markedly accelerated regeneration, with larger regenerating fibers and a higher proportion of newly formed myofibers compared to old WT animals — approaching the regenerative capacity seen in young mice. Mitochondrial fatty acid oxidation was enhanced in knockout muscle, consistent with findings in young HDAC11-deficient animals reported previously by the same group.

Lipidomic profiling of skeletal muscle fatty acids revealed one of the most striking mechanistic findings: HDAC11 deficiency dramatically reduced the omega-6 to omega-3 PUFA ratio and significantly improved the omega-3 index. Age normally shifts muscle lipid composition toward monounsaturated fatty acids and an elevated omega-6/omega-3 ratio, a pattern associated with inflammation and metabolic dysfunction. HDAC11−/− mice resisted this shift. Functionally, old knockout mice outperformed WT controls on grip strength and fatigue resistance tests, directly linking the molecular findings to measurable improvements in physical performance. The authors propose HDAC11 as a bona fide drug target for sarcopenia, noting that selective small-molecule HDAC11 inhibitors have already been developed and could be repurposed for clinical translation.